RxDoctor Payments Data

Pedram Sinai

Sports Medicine · Encino, CANPI 1275995359

Payments from drug & device makers

$513in general payments, 2019–2025

Across 25 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$139
  • AbbVie$84
  • AstraZeneca$81
  • Abbott$60
  • Novo Nordisk$52
  • Amarin Pharma, Inc.$37
  • plus $60 from 4 others

What the payments were for

  • Food & beverage$513100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$513 in reported general payments places this provider in the 35th percentile of 662 sports medicine providers in California.

See all sports medicine providers in California

Medicare billing

Part B allowed, 2024
$239,371
Medicare patients
339
Services billed
5,691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium282$221,850
OzempicSemaglutide26$26,389
Diclofenac Epolamine49$22,403
MounjaroTirzepatide13$13,328
VascepaIcosapent Ethyl29$12,099
RestasisCyclosporine13$4,277
Ventolin HfaAlbuterol Sulfate22$1,265
Albuterol Sulfate HfaAlbuterol Sulfate40$1,260
Famotidine15$395
Olmesartan Medoxomil14$326
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen38$298
Pramipexole DihydrochloridePramipexole Di-Hcl27$194
Fluticasone Propionate31$193
Simvastatin12$165
Gabapentin26$156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$52$26,38926 claims
AbbVieRestasis$84$4,27713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 662 sports medicine providers in California.

Other sports medicine in Encino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →